News

Rituximab may be safe and effective in treating young children with myasthenia gravis (MG) driven by antibodies that target muscle-specific tyrosine kinase (MuSK), according to a report detailing the case of a 4-year-old girl. The girl was one of the youngest MG patients to have received rituximab, according…

Disease-causing antibodies from different myasthenia gravis (MG) patients bind to and affect the function of acetylcholine receptors (AChRs) in different ways, a study finds. While the mechanism varied, all the antibodies ultimately interfered with the usual activation of AChRs, which are the proteins important for normal muscle contractions commonly…

Long-term treatment with nipocalimab led to sustained reductions in symptom severity among antibody-positive patients with generalized myasthenia gravis (gMG) in a Phase 3 clinical trial. That’s according to new data presented by its developer, Johnson & Johnson, at the American Academy of Neurology (AAN) Annual Meeting this…

Treatment with Remegen’s telitacicept over nearly six months safely reduced disease severity in adults with generalized myasthenia gravis (gMG) and helped ease these patients’ symptoms. That’s according to new data from a Phase 3 clinical trial (NCT05737160) that was presented in a late-breaking session at this year’s…

The U.S. Food and Drug Administration (FDA) has approved a version of Argenx’s Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that can be self-administered via a prefilled syringe to treat generalized myasthenia gravis (gMG). These prefilled syringes are indicated for adults with gMG who are positive for antibodies against…

Treatment with the cell therapy Descartes-08 led to long-term reductions in symptom severity for people with myasthenia gravis (MG) taking part in a Phase 2b clinical trial, according to updated data announced by therapy developer Cartesian Therapeutics. “Participants dosed with a single six-week course of treatment of…

Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available in the U.S. to treat adults with generalized myasthenia gravis (gMG) who test positive for antibodies against acetylcholine receptors (AChRs), the most common type of MG-causing antibodies. Besides myasthenia gravis (MG), Epysqli will also be available for…

Problems speaking and swallowing are common among people with myasthenia gravis (MG), but speech-language evaluations and treatment are not carried out as part of routine care for MG patients, a new study by a trio of U.S. researchers has found. Indeed, compared with the general population, individuals with MG…

Scientists in Korea have developed a cell-based test that can be used to detect antibodies against agrin, a protein involved in nerve-muscle communication that is sometimes targeted by harmful autoantibodies in people with myasthenia gravis (MG). The researchers said they validated the test “and have demonstrated that this [cell-based…

UCB’s injection therapy Rystiggo (rozanolixizumab-noli) has been granted regulatory approval in Canada for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins. Anti-AChR or anti-MuSK antibodies — self-reactive antibodies that target the body’s own healthy…